Figure 2. FAT1 is a target of VP in GC.

(a) YAP1 expression in GC cells. Western blot analysis of lysates from the indicated GC cell lines. (b) Gene expression profile. Microarray analysis of AGS and MKN45 GC cell lines in the absence (control) and presence of VP. Venn diagram of genes with significantly different expression between the control and VP-treated groups of two GC cell lines. A univariate test (two-sample t-test) with a multivariate permutation test (10,000 random permutations) was applied. In each comparison, we applied a cut-off p-value of <0.001 to retain genes with expression that differed significantly between the two groups of cells. Expression patterns of selected genes shared in the two cell lines. The expression of only 947 genes was commonly up- or down-regulated in all three cohorts. Colored bars at the top of the heat map represent samples as indicated. (c) Protein expression by Western blotting and (d) mRNA expression by qRT-PCR experiment from cells treated with VP or DMSO (control). (e) Immunohistochemical staining of FAT1 in wild-type (left), K19-C2mE (middle), and Gan (right) mouse stomachs. (f) WB analysis from gastric cancer mouse model used in Figure (2e). (g) FAT1 expression in GC patient cohorts. (h) Patients in the indicated GC cohort from GEO were dichotomized according to expression of FAT1 and patients with relatively high or low expression of FAT1 and was considered for plotting. Data represent the mean ± standard deviation from the indicated samples. A Student's t-test was applied to examine differences for significance.